Navigation Links
Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
Date:5/21/2008

Session: Developmental Therapeutics: Molecular Therapeutics

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-1 p.m. Location: W375a

Poster Number: 5 Abstract Number: 3528

Presenter: Heather A. Wakelee, MD

-- XL880* (MET, VEGFR2) -- Poster

"A phase 2 study of the dual MET/VEGFR2 inhibitor GSK1363089 (XL880)

in patients with papillary renal carcinoma (PRC)"

Day: Saturday, May 31

Session: Genitourinary Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 5G Abstract Number: 5103

Presenter: Ramiprasad Srinivasan, MD, PhD

-- XL765 (PI3K, mTOR) -- Oral Presentation

"A phase 1 dose-escalation study of the safety, pharmacokinetics

(PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765,

administered orally to patients (pts) with advanced solid tumors"

Day: Saturday, May 31

Session: PI-3 Kinase/mTOR Directed Agents

Time: 1:45-2:15 pm

Location: W375a

Abstract Number: 3510

Presenter: Kyriakos Papadopoulis, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

Sunday, June 1

-- XL184 (RET, MET, VEGFR2) -- Oral Presentation

"A phase 1 study of XL184, a RET, VEGFR2, and MET kinase inhibitor,

in patients (pts) with advanced malignancies, including pts with

medullary thyroid cancer (MTC)"

Day: Sunday, June 1

Session: Developmental Therapeutics: Molecular Therapeutics

Time: 10-10:15 a.m.

Location: W375a

Abstract Number: 3522

Presenter: Ravi Salgia, MD, PhD

-- XL647 (EGFR, HER2, VEGFR2) -- Poster

"Activity of XL647 in clinically selected NSCLC patients (pts)

'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 ... equities: Genetic Technologies Ltd (NASDAQ: GENE ), ... Fisher Scientific Inc. (NYSE: TMO ), Sequenom ... (NYSE: PKI ). Free research report on ... . On Thursday, April 30, 2015, the NASDAQ ...
(Date:5/1/2015)... -- According to a new market ... by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), by ... Analysis & Global Forecast to 2019", published by ... Market for the forecast period of 2014 to ... Billion by 2019 from $1.425 Billion in 2014, ...
(Date:4/30/2015)... Spirax Sarco, the leader in product ... announce that for the first time in the company’s ... a Queen’s Award for Innovation – the UK’s highest ... of a unique flowmeter. , The Spirax Sarco ... steam flow measurement. The device provides reliable, accurate ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... Immunotech Laboratories (Pink Sheets: IMMB) is happy ... potential venture for South America, headquartered in Mexico. ... Laboratories, the potential outcome from these discussions, will ... and position the company for a viable regional ...
... FRANCISCO, April 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... development of compounds for the treatment of cardiovascular and ... letter, dated March 31, 2009, from the staff of ... does not currently comply with NASDAQ Marketplace Rule 4310(c)(3). ...
... to leverage technologies for PACS data disaster recoveryCHICAGO, April ... business unit of Siemens Healthcare ( ... Corporation ( www.harris.com ... solutions critical for Picture Archiving and Communication Systems (PACS) ...
Cached Biology Technology:Immunotech Laboratories Announces South American Strategy 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4Siemens Healthcare Announces Planned Collaboration with Harris Corporation 2Siemens Healthcare Announces Planned Collaboration with Harris Corporation 3Siemens Healthcare Announces Planned Collaboration with Harris Corporation 4
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... and Voice Biometrics - Global Strategic Business Report" report to ... Face and Voice Biometrics in US$ Thousands by the following Segments: ... for the US, Canada , Japan ... , Middle East & Africa ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... potential for preventing cardiomyopathy, a form of heart disease that ... scientists have concluded in a new study. Their report, which ... for diabetic cardiomyopathy, appears in ACS, bi-weekly Journal of ... note that people with diabetes have at least twice the ...
... of up to 4.2 C and the end of ... are not revised in the Copenhagen Accord, the international pledge ... conference. Just ahead of the next United ... Tianjin, China, a new report published today, Wednesday, 29 September, ...
... 2010) "Migraine feels like God just punched you in ... his interview on the American Migraine Foundation,s (AMF) new podcast ... crisis." In the interview AMF,s president Barry Baumel MD, ... pain of migraine, how not to be a "nave" patient, ...
Cached Biology News:Climate accord loopholes could spell 4.2-degree rise in temperature and end of coral reefs by 2100 2American Migraine Foundation launches new podcast series 2
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Silica bead method is an economic method of DNA extraction from agarose...
...
...
Biology Products: